X0306
4
2014-02-14
0
0001131324
GENOMIC HEALTH INC
GHDX
0001337334
Shak Steven
301 PENOBSCOT DRIVE
REDWOOD CITY
CA
94063
0
1
0
0
EVP of R&D
Common Stock
2014-02-14
4
M
0
7000
2.88
A
320643
D
Common Stock
2014-02-14
4
S
0
7000
27.3757
D
313643
D
Common Stock
2014-02-15
4
F
0
672
27.62
D
312971
D
Common Stock
2014-02-15
4
F
0
756
27.62
D
312215
D
Common Stock
2014-02-15
4
F
0
627
27.62
D
311588
D
Employee Stock Option (right to buy)
2.88
2014-02-14
4
M
0
7000
0.00
D
2014-12-02
Common Stock
7000
41348
D
This sale of common stock was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on September 9, 2013.
Represents weighted average sale price. Actual sale prices ranged from $27.14 to $27.62.
Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
Includes 4,500 restricted stock units awarded January 27, 2011, of which 1/3 of the shares vest on February 15, 2014, and the 1/3 of the shares that vested on each of February 15, 2012 and 2013, net of withholding.
Includes 5,700 restricted stock units awarded February 5, 2012, of which 1/3 of the shares vest on each of February 15, 2014 and 2015, and the 1/3 of the shares that vested on February 15, 2013, net of withholding.
Includes 5,000 restricted stock units awarded July 25, 2013, of which 1/3 of the shares vest on each of February 15, 2014, 2015 and 2016.
Includes 5,360 restricted stock units awarded January 28, 2014, of which 1/3 of the shares vest on each of February 15, 2015, 2016 and 2017.
Includes 5,700 restricted stock units awarded February 5, 2012, of which 1/3 vest on February 15, 2015, and the 1/3 of the shares that vested on each of February 15, 2013 and 2014, net of withholding.
Includes an aggregate of 10,594 shares of common stock issuable pursuant to previously reported restricted stock units awards that have not vested.
The option became exercisable as to 25% of the shares on December 2, 2005, and becomes exercisable as to 1/48th of the shares each full month thereafter.
/s/ Dean L. Schorno, Attorney-in-fact
2014-02-19